Text Size

Ocular Graft Versus Host Disease After Hematopoietic Stem Cell Transplantation in Adults

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00912067
First received: June 1, 2009
Last updated: NA
Last verified: June 2009
History: No changes posted
  Purpose

The purpose of this study is to evaluate the presence and manifestations of ocular graft versus host disease in adults that had hematopoietic stem cell transplantation in the past 3 years at the sheba medical center, Israel. As well as correlate the degree of the presentation to the therapeutic protocol (chemotherapy and irradiation).


Condition
Graft Versus Host Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Ocular Graft Versus Host Disease After Hematopoietic Stem Cell Transplantation in Adults

Further study details as provided by Sheba Medical Center:

Estimated Enrollment: 120
Study Start Date: July 2009
Groups/Cohorts
hematopoietic stem cell transplantation

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

adults after hematopoietic stem cell transplantation done at sheba medical center Israel during the last 3 years

Criteria

Inclusion Criteria:

  • after hematopoietic stem cell transplantation done at sheba medical center Israel
  • 3 month have past from transplantation but no more then 3 years

Exclusion Criteria:

  • transplantation done in the last 3 month or more than 3 years have past since
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00912067

Locations
Israel
Sheba Medical Center
Tel Hashomer, Israel, 52621
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: irina barequet, MD Sheba Medical Center
  More Information

Publications:

Responsible Party: Irina Barequet MD/PI, Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00912067     History of Changes
Other Study ID Numbers: SHEBA-09-7085-IB-CTIL
Study First Received: June 1, 2009
Last Updated: June 1, 2009
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases

ClinicalTrials.gov processed this record on May 23, 2013